Raymond James Financial’s Ocular Therapeutix OCUL Stock Holding History

Raymond James Financial’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.28M	Buy	859,485 +17,298	+2%	+$165K	﹤0.01%	2277
2025 Q4	$10.2M	Sell	842,187 -169,782	-17%	-$2.06M	﹤0.01%	1944
2025 Q3	$11.8M	Buy	1,011,969 +127,588	+14%	+$1.53M	﹤0.01%	1789
2025 Q2	$8.21M	Buy	884,381 +520,138	+143%	+$4.07M	﹤0.01%	2020
2025 Q1	$2.67M	Buy	364,243 +162,620	+81%	+$1.25M	﹤0.01%	2786
2024 Q4	$1.72M	Buy	+201,623	New	+$1.97M	﹤0.01%	3068

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Raymond James Financial's OCUL Position: Q1 2026 in Review

Raymond James Financial increased its Ocular Therapeutix (OCUL) stake by 2.1% in Q1 2026, buying an estimated $165K and bringing the position to 859,485 shares worth $7.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Raymond James Financial first reported a position in OCUL in Q4 2024 and has held it in 6 quarters since. The position peaked at $11.8M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Raymond James Financial held 859,485 shares of Ocular Therapeutix worth $7.28M as of Q1 2026.
Raymond James Financial bought 17,298 Ocular Therapeutix shares in Q1 2026, an estimated $165K.
Ocular Therapeutix made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2277 holding.
Raymond James Financial first reported a position in Ocular Therapeutix in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Ocular Therapeutix position peaked at $11.8M in Q3 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.